Reaction Details Report a problem with these data
Target
Mitogen-activated protein kinase 9
Ligand
BDBM50363459
Substrate
n/a
Meas. Tech.
ChEMBL_800185 (CHEMBL1947747)
IC50
140±n/a nM
Citation
Krenitsky, VP; Delgado, M; Nadolny, L; Sahasrabudhe, K; Ayala, L; Clareen, SS; Hilgraf, R; Albers, R; Kois, A; Hughes, K; Wright, J; Nowakowski, J; Sudbeck, E; Ghosh, S; Bahmanyar, S; Chamberlain, P; Muir, J; Cathers, BE; Giegel, D; Xu, L; Celeridad, M; Moghaddam, M; Khatsenko, O; Omholt, P; Katz, J; Pai, S; Fan, R; Tang, Y; Shirley, MA; Benish, B; Blease, K; Raymon, H; Bhagwat, S; Henderson, I; Cole, AG; Bennett, B; Satoh, Y Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett 22:1427-32 (2012) [PubMed] Article
More Info.:
Target
Name:
Mitogen-activated protein kinase 9
Synonyms:
JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2)
Type:
Enzyme
Mol. Mass.:
48131.49
Organism:
Homo sapiens (Human)
Description:
JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology).
Residue:
424
Sequence:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR